Lilly, Novo Nordisk near White House deals on obesity drug prices, Endpoints News reports
PositiveFinancial Markets

Lilly and Novo Nordisk are reportedly close to reaching agreements with the White House regarding the pricing of obesity drugs. This development is significant as it could lead to more affordable treatment options for millions struggling with obesity, potentially improving public health outcomes and reducing healthcare costs. The negotiations highlight the growing recognition of obesity as a critical health issue and the need for accessible solutions.
— Curated by the World Pulse Now AI Editorial System












